Cancer Rx Reimbursement Made Smoother By Survival Benefit, Genentech Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Survival data also helps oncologics avoid possible safety issues, CFO Ebersman said. Furthermore, if a product shows a survival benefit it creates an effective defensive strategy by establishing itself as standard of care.
You may also be interested in...
Genentech Plans Herceptin Early-Stage Breast Cancer Submission
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.
Genentech Plans Herceptin Early-Stage Breast Cancer Submission
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.
Avastin Lung Cancer Reimbursement Will Be Case By Case, Genentech Says
The company says it is too early to determine the extent of off-label use of Avastin in lung cancer. Genentech will present data on use of Avastin alone, as well as in combination with Tarceva, for the treatment of lung cancer at ASCO's annual meeting in May.